肝脏III型固有淋巴细胞编程对肝纤维化进程的免疫调控及机制研究

基本信息
批准号:81670541
项目类别:面上项目
资助金额:58.00
负责人:蒋炜
学科分类:
依托单位:复旦大学
批准年份:2016
结题年份:2020
起止时间:2017-01-01 - 2020-12-31
项目状态: 已结题
项目参与者:王思奇,刘云,吴盛迪,赵媛,方颖,刘黎黎,佘为民,詹延霞
关键词:
肝纤维化固有淋巴细胞细胞编程免疫调控
结项摘要

Liver fibrosis is the intermediate link and reversible stage during the development of chronic liver disease to cirrhosis. The pathological immune responses can change hepatic immune homeostasis and immune microenvironment, which lead to the progression of liver fibrosis. Previously, the role of the homeostasis of hepatic CD4+T cells in the process of liver fibrosis had been illustrated and proved in our concluded project of NSFC (No.81070341). The balance of hepatic and peripheral regulatory T cells (Tregs)/T helper 17 cells (Th17) tended to Th17 dominance in the process of liver fibrosis along with the increased secretion of the associated cytokines by Th17 cells. Furthermore, the enhanced functions of Th17 cells promoted the pro-fibrotic functions of hepatic stellate cells (HSCs) and influenced the progression of liver fibrosis. On the other hand, innate immune functions play key roles in the regulation of liver fibrosis. Since the immune regulatory functions of the classical innate immune cells such as NK and NKT cells have been gradually elucidated, innate lymphoid cells (ILCs), which plays key roles in the regulation of tissue homeostasis and inflammatory infection, have been discovered due to the new understanding and classification of the phenotypes and functions of innate immune cells recently. Group III ILCs (RORγt+ILCs, ILC3s) not only own the same transcription factors as Th17 cells but also secret the similar Th17 associated cytokines to regulate the immune response, thus it may be an important link between hepatic innate and adaptive immune responses in the process of liver fibrosis. We have verified that the altered numbers and functions of hepatic ILC3s exist in the patients with chronic liver disease in the pre-experiments. Furthermore, cell programming is not only the results of the local microenvironment changes, but also the necessary conditions to obtain the specific phenotypic and functional characteristics and play the important immune regulatory functions at the specific sites. In this research, we will firstly observe the relationship between the hepatic subsets of ILC3s and pathological grades and states of liver fibrosis. And then, by using the techniques of flow cytometry and molecular biology, we will investigate the pro-chemotactic functions of Kupffer cells on hepatic ILC3s, identify specific programming of ILC3s under the microenvironment of liver fibrosis, and further testify the immune regulatory roles of CD4+T cells in programming of hepatic ILC3s to illustrate the adaptive regulation of innate lymphocytes responses and the maintenance of immune homeostasis through ILC3/T cell interactions under hepatic local microenvironment in the process of liver fibrosis. Finally, we will analyze the regulation of hepatic ILC3s on the fibrotic function of HSCs. Based on the above-mentioned research, we look forward to elaborating the network regulation and the specific mechanism between the immune cells of liver in the process of liver fibrosis. We hope these achievements can contribute to the basic theory and practical applications for the future clinical immunotherapy on liver fibrosis.

病理状态下的免疫应答是调控肝纤维化进程重要因素。我们NSFC课题研究表明:肝脏CD4+T细胞稳态改变影响肝纤维化进程,Th17表达及功能的增强调节HSCs促纤维化功能。新近发现固有淋巴细胞(ILCs)的重要免疫来源,其中III型ILCs(ILC3s)具有与Th17相同转录因子并分泌类似细胞因子,预实验证实慢性肝病患者肝脏ILC3s数量及功能的改变,而细胞编程不仅是局部微环境变化的结果,也是获得特异表型和功能特征、并在特定部位发挥免疫调控的必要条件。本研究将运用流式细胞术及分子生物学手段,以肝脏ILC3s及亚群与肝纤维化程度分析为基础,明确ILC3s在肝纤维化微环境中的特异性编程,论证CD4+T细胞对ILC3s编程的调控及对肝纤维化肝脏局部免疫稳态的协调,观察ILC3s对肝纤维化进程及对HSCs功能的影响,阐述肝纤维化时肝脏局部固有免疫与适应免疫应答网络调控,为免疫治疗肝纤维化提供理论基础。

项目摘要

病理状态下的免疫应答是调控肝纤维化进程重要因素。肝脏CD4+T细胞稳态改变影响肝纤维化进程,Th17表达及功能的增强调节肝星状细胞促纤维化功能。新近发现固有淋巴细胞(ILCs)的在多种疾病中发挥重要的作用,其中III型ILCs(ILC3s)具有与Th17相同转录因子并分泌类似细胞因子。本研究运用流式细胞术及分子生物学手段,证实慢性肝病患者肝脏ILC3s数量增多,同时细胞因子(IL-17A、IL-22、TNF-α、IFN-γ)表达也增加。细胞体外功能培养也证明ILC3s可通过分泌IL-17A及IL-22激活肝星状细胞。同样地,在四氯化碳诱导的肝纤维化小鼠模型中,我们也证明了ILC3s数量及功能与在人体中的有相同的改变。体外ILCs的敲除及ILC3s的过继转移进一步证明了ILC3s的促进纤维化的功能。本研究阐述了肝纤维化时肝脏局部固有免疫与适应免疫应答网络调控,为免疫治疗肝纤维化提供理论基础。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

病毒性脑炎患儿脑电图、神经功能、免疫功能及相关因子水平检测与意义

病毒性脑炎患儿脑电图、神经功能、免疫功能及相关因子水平检测与意义

DOI:10.13210/j.cnki.jhmu.20190508.001
发表时间:2019
2

奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展

奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展

DOI:
发表时间:2020
3

结直肠癌免疫治疗的多模态影像及分子影像评估

结直肠癌免疫治疗的多模态影像及分子影像评估

DOI:10.13609/j.cnki.1000-0313.2022.04.019
发表时间:2022
4

TRPV1/SIRT1介导吴茱萸次碱抗Ang Ⅱ诱导的血管平滑肌细胞衰老

TRPV1/SIRT1介导吴茱萸次碱抗Ang Ⅱ诱导的血管平滑肌细胞衰老

DOI:10.3969/j.issn.1001-1978.2022.02.019
发表时间:2022
5

组蛋白去乙酰化酶在变应性鼻炎鼻黏膜上皮中的表达研究

组蛋白去乙酰化酶在变应性鼻炎鼻黏膜上皮中的表达研究

DOI:10.16066/j.1672-7002.2021.06.013
发表时间:2021

蒋炜的其他基金

批准号:21176157
批准年份:2011
资助金额:60.00
项目类别:面上项目
批准号:21676168
批准年份:2016
资助金额:64.00
项目类别:面上项目
批准号:81270517
批准年份:2012
资助金额:70.00
项目类别:面上项目
批准号:81070341
批准年份:2010
资助金额:32.00
项目类别:面上项目
批准号:20806050
批准年份:2008
资助金额:18.00
项目类别:青年科学基金项目
批准号:71172131
批准年份:2011
资助金额:42.00
项目类别:面上项目
批准号:21476146
批准年份:2014
资助金额:80.00
项目类别:面上项目
批准号:30300151
批准年份:2003
资助金额:20.00
项目类别:青年科学基金项目
批准号:71531010
批准年份:2015
资助金额:310.00
项目类别:重点项目

相似国自然基金

1

可溶性MULT1通过活化肝脏固有淋巴细胞调控血吸虫病肝纤维化的机制研究

批准号:81772221
批准年份:2017
负责人:陆盛军
学科分类:H2203
资助金额:56.00
项目类别:面上项目
2

调节性B细胞在肝纤维化进程中的免疫调控作用及机制研究

批准号:81270517
批准年份:2012
负责人:蒋炜
学科分类:H0310
资助金额:70.00
项目类别:面上项目
3

肝星状细胞的免疫调控功能在肝纤维化进程中的作用

批准号:81070341
批准年份:2010
负责人:蒋炜
学科分类:H0310
资助金额:32.00
项目类别:面上项目
4

肝纤维化进程中胆汁酸-肠道菌群-肝脏互作网络异常的机制研究

批准号:81770584
批准年份:2017
负责人:刘小伟
学科分类:H0307
资助金额:60.00
项目类别:面上项目